Skip to main content
. Author manuscript; available in PMC: 2016 Jan 6.
Published in final edited form as: J Am Chem Soc. 2015 Feb 20;137(8):2967–2974. doi: 10.1021/ja511978y

Table 2.

IC50 values (nM) of 1, 2, and cisplatin against a panel of cisplatin-resistant cell lines and quiescent lung carcinoma A549 cells after 72 h exposure. The errors represent standard deviations.

Cell line Cancer type 1 2 cisplatin
HT-29 Colorectal adenocarcinoma 85 ± 11 95 ± 20 29640 ± 1329
MDA-MB-231 Breast adenocarcinoma 475 ± 161 1735 ± 275 43600 ± 7071
MCF-7 Breast adenocarcinoma 285 ± 35 805 ± 21 9740 ± 537
PC-3 Prostate adenocarcinoma 270 ± 14 780 ± 10 10250 ± 919
DU 145 Prostate carcinoma 2840 ± 381 1370 ± 84 > 100000
A549 (quiescent) Lung carcinoma 8610 ± 749 5245 ± 1986 9420 ± 1937